OSLI Retina

October 2018

Issue link: http://osliretina.healio.com/i/1039004

Contents of this Issue


Page 85 of 87

820 Ophthalmic Surgery, Lasers & Imaging Retina | Healio.com/OSLIRetina 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-848-1000 Email: osli@healio.com Healio.com/OSLIRetina SLACK I N C O R P O R A T E D ® SLACK Incorporated Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson Operations Manager Cheryl McKeown Production Associate Ryan Davis SALES Group Sales Director, Eye Care Scott Wright National Account Manager Laura Renna Director, Sales Administration and Support Carolyn Boerner Sales Administrator Wanda Granato Recruitment/Classified Sales Representative Bernadette Hamilton Sales Coordinator, Recruitment Jennifer Carroll Director of Audience Development Stephanie McHugh Reprints/Eprints Licensing Opportunities: The Sheridan Press 800-635-7181 ext. 8065 DESIGN Creative Director Thomas Cavallaro The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker Follow OSLIJournal OSLI Retina SLACK Incorporated News and Notes Novartis to Seek ROP Indication for Lucentis Novartis announced it will file for a new indication for Lucentis for the treat- ment of retinopathy of prematurity (ROP), according to a company press release. The filing will be based on the "favorable benefit-risk profile" of the phase 3 RAINBOW study of Lucentis (ranibizumab; Novartis/Genentech, South San Francisco, CA) versus laser surgery for the treatment of ROP in premature infants. The study, presented at the Euretina meeting, "marginally" missed statisti- cal significance for its primary endpoint (P = .0254, compared with the signifi- cance level of P = .025), the difference in success between the Lucentis 0.2 mg and 0.1 mg groups compared with laser surgery. The Lucentis 0.2 mg group had an 80% success rate, the Lucentis 0.1 mg group a 75% success rate, and the laser surgery group a 66.2% success rate, according to the release. Lucentis does not damage eye tissue, which is possible with laser surgery, the release said. Instead, it pharmacologically targets and reduces the elevated intraocular level of vascular endothelial growth factor, which is the underlying cause of ROP. "The RAINBOW study is part of our ongoing commitment to addressing the most urgent needs in eye care. We look forward to filing outside the U.S. for an indication in ROP, which may bring us one step closer to reimagining care for these premature infants," Dirk Sauer, development unit head of Novartis Oph- thalmology, said in the release. Originally posted on Healio.com on September 24, 2018. Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2018. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $222, electronic only: $197. Institutional: One year—$692. Residents and fellows: $111 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $71 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $99. Payment must accompany order. Subscrip- tion requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - October 2018